These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2194500)

  • 1. Recombinant targeted proteins for biotherapy.
    Ahmad A; Law K
    Mol Biother; 1990 Jun; 2(2):67-73. PubMed ID: 2194500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].
    Chiron MF
    Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cancer therapy by using bispecific antibody].
    Azuma A; Niitani H; Okumura K
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant toxins for the treatment of cancer.
    Kreitman RJ
    Curr Opin Mol Ther; 2003 Feb; 5(1):44-51. PubMed ID: 12669470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies in the therapy of colon cancer.
    Welt S; Ritter G
    Semin Oncol; 1999 Dec; 26(6):683-90. PubMed ID: 10606261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical applications of monoclonal antibodies.
    Clark MR
    Revis Biol Celular; 1986; 9():1-79. PubMed ID: 3324213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
    Melani C; Figini M; Nicosia D; Luison E; Ramakrishna V; Casorati G; Parmiani G; Eshhar Z; Canevari S; Colombo MP
    Cancer Res; 1998 Sep; 58(18):4146-54. PubMed ID: 9751627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new class of antigen-specific killer cells.
    Yang AG; Chen SY
    Nat Biotechnol; 1997 Jan; 15(1):46-51. PubMed ID: 9035105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fusion-proteins as biopharmaceuticals--applications and challenges.
    Schmidt SR
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):284-95. PubMed ID: 19333874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
    Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
    Brinkmann U
    In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric fusion proteins--Pseudomonas exotoxin-based.
    Kreitman RJ
    Curr Opin Investig Drugs; 2001 Sep; 2(9):1282-93. PubMed ID: 11717817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies and fusion proteins in medicine.
    Liossis SN; Tsokos GC
    J Allergy Clin Immunol; 2005 Oct; 116(4):721-9; quiz 730. PubMed ID: 16210042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
    Xiang J
    Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant heregulin-Pseudomonas exotoxin fusion proteins: interactions with the heregulin receptors and antitumor activity in vivo.
    Yang D; Kuan CT; Payne J; Kihara A; Murray A; Wang LM; Alimandi M; Pierce JH; Pastan I; Lippman ME
    Clin Cancer Res; 1998 Apr; 4(4):993-1004. PubMed ID: 9563895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for cancer: construction, expression and functional characterization of chimeric antibodies.
    Motmans K; Thirion S; Heyligen H; Janssens J; Raus J; Vandevyver C
    Eur J Cancer Prev; 1996 Dec; 5(6):512-9. PubMed ID: 9061286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.